Monash researchers outsmart superbug


Wednesday, 13 January, 2021


Monash researchers outsmart superbug

A team of Monash researchers has discovered how to revert antibiotic resistance in one of the most dangerous superbugs: Acinetobacter baumannii — responsible for up to 20% of infections in intensive care units.

Published in Nature Microbiology, the research paper describes the use of bacteriophages — also known as ‘phages’ — to kill A. baumannii, pinpointing how the superbug becomes resistant to attack from phages, and in doing so, loses its resistance to antibiotics.

“Phages are viruses, but they cannot harm humans,” lead study author Dr Fernando Gordillo Altamirano from the Monash University School of Biological Sciences said.

“They only kill bacteria.”

Dr Jeremy Barr — senior study author, Group Leader at the School of Biological Sciences and part of the Centre to Impact AMR — added, “We have a large panel of phages that are able to kill antibiotic-resistant A. baumannii. But this superbug is smart, and in the same way it becomes resistant to antibiotics, it also quickly becomes resistant to our phages.”

Dr Altamirano explained that A. baumannii produces a capsule — a viscous and sticky outer layer that protects it and stops the entry of antibiotics.

“Our phages use that same capsule as their port of entry to infect the bacterial cell,” Dr Altamirano said.

“In an effort to escape from the phages, A. baumannii stops producing its capsule — and that’s when we can hit it with the antibiotics it used to resist.”

The study showed resensitisation to at least seven different antibiotics.

“This greatly expands the resources to treat A. baumannii infections,” Dr Barr said. “We’re making this superbug a lot less scary.”

Even though more research is needed before this therapeutic strategy can be applied in the clinic, the prospects are encouraging.

Image credit: ©stock.adobe.com/au/vrx123

Related Articles

Oral care and the prevention of hospital-acquired pneumonia: new evidence for infection prevention and control practice

The HAPPEN randomised control trial involved 8870 patients across three Australian hospitals. Two...

"Pointless scans" to diagnose knee osteoarthritis may trigger inappropriate care, the Commission warns

The warning is informed by the Australian Commission on Safety and Quality in Health Care's...

"Hell in a handbasin": infection considerations of four handbasin design features

An Australian-led review has compared healthcare handbasin design guidelines across 39 countries...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd